A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants
| Autor: | John D. Clemens, Vibhu Kanchan, Sheikh Farzana Zaman, Sachin Kale, Asma Binte Aziz, Davinder Gill, Ajitpal Singh, Farzana Zaman, Wasif A. Khan, Khalequ Zaman, Michelle G. Goveia, Susan S. Kaplan, Mohammad Yunus, Syed Khalid Ali, Mahbuba Khanam, Warda Haque, Mohammad Mahbubul Karim |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
safety
Adult Rotavirus medicine.medical_specialty Hot Temperature 030231 tropical medicine Immunology reactogenicity immunogenicity Antibodies Viral Vaccines Attenuated Placebo medicine.disease_cause Rotavirus Infections 03 medical and health sciences Immunogenicity Vaccine 0302 clinical medicine Double-Blind Method Internal medicine medicine Animals Humans Immunology and Allergy 030212 general & internal medicine Adverse effect Feces Pharmacology Bangladesh Reactogenicity business.industry Immunogenicity Rotavirus Vaccines Infant Rotavirus vaccine Titer Heat stable rotavirus vaccine randomized Cattle business Research Paper |
| Zdroj: | Human Vaccines & Immunotherapeutics |
| ISSN: | 2164-554X 2164-5515 |
| Popis: | Objectives: To assess the safety and reactogenicity of single oral dose of heat-stable rotavirus vaccine (HSRV) in healthy adults aged 18–45 years followed by assessment of safety, reactogenicity, and immunogenicity of three doses of HSRV in healthy infants aged 6–8 weeks at enrollment. Trial Design: Single-center randomized controlled, sequential, blinded (adults) and open-label (infants). Setting: Single site at International Center for Diarrheal Disease Research, Bangladesh (icddr,b). Participants: Fifty eligible adults randomized in 1:1 ratio (HSRV: Placebo) followed by 50 eligible infants randomized in 1:1 ratio (HSRV: Comparator (RotaTeq®, pentavalent human-bovine (WC3) reassortant live-attenuated, rotavirus vaccine)). Intervention: Adults received either a single dose of HSRV or placebo and followed for 14 days. Infants received three doses of either HSRV or comparator with a follow-up for 28 days after each dose. Main Outcome Measures: Solicited and unsolicited adverse events (AEs) along with any serious adverse events (SAEs) were part of the safety and reactogenicity assessment in adults and infants whereas serum anti-rotavirus IgA response rates were part of immunogenicity assessment in infants only. Post-vaccination fecal shedding of vaccine-virus rotavirus strains was also determined in adults and infants. Results: In this study, HSRV, when compared with placebo, did not result in increase in solicited adverse events (solicited AEs) in adults. In infants, HSRV had a safety profile similar to comparator vis-à-vis solicited AEs. In infants, fecal shedding of vaccine-virus strains was not detected in HSRV recipients but was observed in two comparator recipients. Percentage of infants exhibiting threefold rise in serum anti-rotavirus IgA titers from baseline to 1-month post-dose 3 in HSRV group was 88% (22/25) and 84% (21/25) in comparator group. Conclusion: HSRV was found to be generally well-tolerated in both adults and infants and immunogenic in infants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|